141 results about "Chemokine" patented technology

Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The present application relates to a pharmaceutical composition for wound treatment. Specifically, the present application concerns a composition including a wound-coating material and chemokine-adsorbing particles to absorb inflammatory chemokines that cause excessive immune responses, thereby allowing active wound healing.

Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.

The invention provides hydrogel, a porous titanium / hydrogel composite implant material and a preparation method of the porous titanium / hydrogel composite implant material. The hydrogel is obtained by photo-crosslinking and curing a hydrogel precursor solution containing acrylated beta-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor. The hydrogel has a porous network structure, high elastic modulus, high fatigue resistance and excellent biocompatibility, and also has the capability of recruiting bone marrow mesenchymal stem cells (BMSCs) and the capability of promoting osteogenic differentiation of the BMSCs; the porous titanium / hydrogel composite implant material prepared from the hydrogel can effectively promote the growth of new bone tissues, has excellent osseointegration capability, obviously improves the osteogenesis repair effect and the osseointegration effect, provides a new treatment approach for the repair treatment of segmental bone defects, and has important medical significance.

Embodiments of the disclosure include methods and compositions for the treatment of splenomegaly. In specific embodiments, fibroblasts and / or fibroblast-derived materials, are utilized in at least some cases to affect the immune response of the individual in order to reduce the pathogenic levels of immune cells or cytokines and / or chemokines excreted by those immune cells.

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The present application relates to a model for predicting the age of a rat, which considers data of immune cells, or data of immune cells, and data of cytokine and / or chemokine levels to predict the age of a rat. The model of the present application significantly improves the accuracy and reliability of age prediction, provides strong support for personalized health management, and helps to promote the development of precision medicine, and ultimately aims to achieve the goal of extending healthy life.

The invention belongs to the technical field of biology, and particularly relates to application of a herba artemisiae scopariae aqueous extract in enhancing liver chemotaxis of adipose-derived mesenchymal stem cells. In order to provide a way for enhancing the liver chemotaxis of the adipose-derived stem cells, the capillary artemisia aqueous extract is used for improving the expression level of chemotactic factors of the adipose-derived stem cells in vitro and intervening the proliferation, migration and chemotaxis capabilities of the adipose-derived stem cells to liver cells, the concentration of the capillary artemisia aqueous extract is 0.5 mg / mL to 1 mg / mL, the chemotaxis time is 24 h to 48 h, and the capillary artemisia aqueous extract is used for enhancing the liver chemotaxis of the adipose-derived stem cells. And the chemotactic factors are CCR1 and CXCR4.

The application discloses application of a reagent for detecting chemokine ligand 9 in preparation of a myocarditis early detection product. The application identifies immune cell characteristics in a mouse myocarditis early stage by using single cell RNA sequencing technology, and finds that compared with healthy mice, myocarditis mice have more macrophages infiltrating myocardial tissue and expressing chemokine ligand 9, which reveals that the chemokine ligand 9 can be used as a specific target for detecting acute myocarditis. Further, the application uses BPBBT, DSPE-mPEG 2000 and DSPE-PEG 2000 -MAL to prepare nanoparticles, designs a targeting peptide capable of specifically combining with the chemokine ligand 9 and connects the targeting peptide to a surface of the nano material, and thus myocarditis targeted nano probes are prepared. The myocarditis targeted nano probes can specifically gather in an inflammation area, and thus myocarditis can be accurately detected.

The invention belongs to the technical field of tumor immunity, and particularly relates to a tumor antigen and chemotactic factor co-coding system and application thereof. The invention provides a tumor antigen and chemotactic factor co-coding system. The tumor antigen and chemotactic factor co-coding system comprises a nucleotide sequence for coding a tumor antigen and a nucleotide sequence for coding a chemotactic factor. The tumor antigen and chemotactic factor co-coding system can flexibly replace an antigen sequence and chemotactic factor combination, is adaptive to different tumor types and various immunotherapy requirements, can be expanded to various solid tumor treatment scenes through a customized antigen-chemotactic factor combination in the future, and has a wide application prospect. The broad-spectrum application in tumor treatment means including tumor neoantigen vaccines, adoptive cell therapy and the like is realized.

The invention relates to application of an organic compound in preparation of a medicine for preventing or treating neuroinflammation related diseases, and belongs to the technical field of medicinal chemistry. It is found that the organic compound with the chemical structural formula shown in the formula (I)-(IV) can remarkably inhibit the expression level of proinflammatory factors and chemotactic factors in a microglial cell inflammation model and has a broad-spectrum anti-inflammatory effect, and therefore the organic compound has the effect of preventing or treating neuroinflammation related diseases. The invention develops new application of the organic compounds as shown in the formulas (I)-(IV), and also provides a new therapeutic drug for preventing or treating neuroinflammation related diseases.

The invention provides an application of N4BP1 in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and particularly provides an application of N4BP1 as an inhibition target in preparation of an anti-enteritis drug. Researches show that the deletion of N4BP1 can alleviate colon pathological changes and weight loss caused by DSS, increase the survival days of mice, and reduce the generation of inflammatory factors and chemotactic factors. In addition, DSS can cause increase of N4BP1 expression in mice. Therefore, occurrence and development of enteritis can be inhibited by knocking out the N4BP1, the N4BP1 inhibitor or the N4BP1 neutralizing antibody, namely, the N4BP1 can become a new target spot for treating enteritis. Meanwhile, the expression of the N4BP1 can also be used as a new index for enteritis detection.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

The present application relates to a kind of based on chemotactic factor CXCL12 mutant modification double specific fusion protein and its application as immune checkpoint molecule targeted degradation platform in tumor immunotherapy, belong to biological medicine field.The specific problem of the present application is how to effectively enhance the effect of tumor immunotherapy, especially solve the problem of immune escape phenomenon in tumor microenvironment in traditional immunotherapy.To this end, the present application proposes a new KineTAC targeted degradation platform, specifically designs a new chemotactic factor CXCL12 and target protein binding polypeptide (such as anti-PD-1 / PD-L1 monoclonal antibody, anti-LAG-3 monoclonal antibody, etc.) Fusion expression protein molecule, enhance its binding affinity with receptor CXCR4 and CXCR7, and avoid stimulating tumor cell growth proliferation.The fusion protein can target and degrade the immunosuppressive molecules on the surface of tumor cells and immune cells, thereby enhancing the immune response of immune cells and improving the anti-tumor effect.

The present invention discloses the use of tazemetostat in the preparation of drugs for treating acute kidney injury, and belongs to the field of biomedicine technology. Specifically, it also relates to the use of tazemetostat in the preparation of drugs for reducing the mRNA expression levels of lipocalin Ngal, kidney injury factor KIM1, chemokine MCP-1, inflammatory factors IL-1β, IL-6, and TNF-α, and the use of tazemetostat in the preparation of drugs for reducing the levels of creatinine and urea nitrogen in serum. Beneficial effect: The present invention proposes a new drug use of tazemetostat in the treatment of acute kidney injury. It effectively reduces the inflammatory response and renal damage level caused in an in vitro model of acute kidney injury; it can also reduce the expression levels of inflammatory factors IL-6 and chemokine MCP-1 in the serum of an in vivo animal model of renal injury, improve the kidney tissue pathology of animals with acute kidney injury, inhibit the protein expression of KIM1 in kidney tissue, reduce the levels of creatinine and urea nitrogen in kidney tissue serum, and has a potential therapeutic effect on acute kidney injury.

The invention provides application of a flavin monooxygenase 3 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of medicines. The flavin monooxygenase 3 inhibitor is methimazole or a pharmaceutically acceptable salt, a prodrug or a derivative of methimazole. Experimental results show that after the methimazole is orally taken, the nidus area of animal pancreatitis is obviously reduced, the pathological score is obviously improved, the in-vivo inflammation level is obviously inhibited, and the blood amylase and lipase levels are obviously reduced; the levels of pancreatitis factors and chemotactic factors are reduced, and the oxidative stress index is reduced. In addition, by combining methimazole with the traditional Chinese medicine monomer for inhibiting the trimethylamine oxide level, the curative effect is better. Compared with the prior art, the application has the advantages that the core regulation effect of the trimethylamine oxide in the pathological process of the acute pancreatitis is disclosed for the first time, the limitation of the traditional anti-inflammatory or enzyme replacement therapy is broken through, and the acute pancreatitis is treated by inhibiting the trimethylamine oxide level by inhibiting the flavin monooxygenase 3.

The purpose of the present invention is to suppress the effect of ultraviolet light on melanocytes. Upon performance of gene expression analysis with a focus on the olfactory receptor OR2L13 expressed by melanocytes, it was discovered that addition of (−)-carvone, a ligand of OR2L13, increased the expression of genes related to suppression of active oxygen, suppression of the production of inflammatory cytokines or chemokines, suppression of senescence, and / or degradation of abnormal proteins. As a result of said discovery, the present invention provides an inhibitor of the effects of ultraviolet light on melanocytes that includes (−)-carvone.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.

The invention relates to the technical field of medicines, and particularly discloses an engineered drug-loaded macrophage for resisting transplant rejection. PD-L1 is overexpressed on the surface of a cell membrane of the engineered drug-loaded macrophage, and the engineered drug-loaded macrophage internally contains nanoparticles encapsulated with rapamycin. Due to the biological characteristic that the macrophages can respond to inflammation signals, the engineered drug-loaded macrophages can be efficiently recruited to rejection reaction parts by chemotactic factors of transplantation parts, and the engineered drug-loaded macrophages can penetrate a tissue barrier as an active carrier, respond to external stimulation to exocytosis and release nanoparticles encapsulated with rapamycin after reaching a target position, and can be used for preparing a drug carrier. Local precise delivery of PD-L1 and rapamycin is realized, and immunosuppression toxicity of systemic administration is reduced.

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.

Provided are a chemokine CXCL12 fusion protein and a use thereof. The chemokine CXCL12 fusion protein comprises the chemokine CXCL12 and an antibody against a tumor-associated antigen. The chemokine CXCL12 and the antibody against the tumor-associated antigen are directly fused or fused by means of a linker. On the one hand, the provided chemokine CXCL12 fusion protein can promote T cell infiltration and improve targeting. On the other hand, T cell killing signals are highly dependent on target cells, and T cells generate immune signals to kill the target cells only upon coming into contact with the target cells under the mediation of the fusion protein, thereby reducing toxic side effects.

The invention relates to the field of medicines, in particular to application of a reagent for detecting a complement factor in preparation of a tinnitus diagnostic product, the complement factor is selected from a complement component, a complement regulatory protein or a complement related chemotactic factor, the complement component is selected from C3, C5 and / or C1q, and tinnitus is chronic tinnitus. The peripheral blood can be used as a sample, the chronic tinnitus can be accurately diagnosed, theoretical and experimental bases are provided for clinical diagnosis of the chronic tinnitus, diagnosis and intervention can be carried out in the early stage of tinnitus, and further deterioration is prevented.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The invention discloses application of sulforaphane in preparation of a medicine for treating vascular endothelial impairment, and relates to the technical field of medicines. In-vitro cell experiments prove that the sulforaphane can effectively relieve inflammatory response and activation state of endothelial cells by inhibiting expression of classical adhesion molecules such as SELE, VCAM1 and ICAM1 and various chemotactic factors, so that TNF-alpha induced monocyte adhesion is inhibited; besides, the sulforaphane enhances the anti-oxidation defense capability of endothelial cells by activating an Nrf2 signal channel, effectively relieves oxidative stress injury and plays a role in protecting endothelium; animal experiments further prove that in an atherosclerosis and hypertension mouse model, the sulforaphane down-regulates the expression of adhesion molecules in endothelial cells and up-regulates the expression of antioxidant proteins and vasodilatation promoting proteins at the same time, so that the obvious anti-atherosclerosis and antihypertensive effects are achieved.